Clinical trials: Nondiabetic
Insulin Sensitivity
The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects
The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.
- Trial name
- NCT02586168
- Testing
- Gemcabene 900 mg
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Weight Management
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2…
- Trial name
- NCT06562907
- Testing
- GS-4571, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.
- Trial name
- NCT00335699
- Testing
- Rosuvastatin
- Where
- 7 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Obesity
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
- Trial name
- NCT06886126
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Gastroparesis, Gastroparesis Nondiabetic
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life…
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- EXPEDITE (NCT06560307)
- Testing
- Enterra Therapy System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Obesity
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
- Trial name
- NCT00650806
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Coronary Artery Disease, Chest Pain
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease.
- Conditions
- Coronary Artery Disease, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease
- Trial name
- COMPASS (NCT01117506)
- Testing
- Corus CAD (ASGES)
- Where
- 7 sites in United States
- Volunteers
- 581 people
- Sponsor
- CardioDx
Gastroparesis, Gastroparesis Nondiabetic
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- RESTING (NCT05980455)
- Testing
- Enterra® Therapy System
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.